Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve the Un-audited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has informed BSE that a meeting of its Board of Directors is scheduled for Thursday, November 13, 2025. The main agenda is to consider and approve the Un-audited Financial Results for the quarter and half year ended September 30, 2025, along with the Limited Review Report. The company's trading window for designated persons and their immediate relatives has remained closed since October 1, 2025, and will stay closed until 48 hours after the declaration of the Q2/H1 results. The intimation is filed under Regulation 29 of SEBI LODR, which is a standard compliance requirement before announcing quarterly financial results.
No direct impact on the stock price from this notice itself — it is a routine regulatory disclosure. Investors should watch for the actual Q2 and H1 FY26 results expected shortly after November 13, which will give the first real read on the company's earnings performance for the half-year.